Reference number : 236-2012-2013-Q4-00674, amendment number : , agreement type : G, recipient legal name : BAHLIS, Nizar J, recipient country : CA, recipient province : AB, recipient city : Calgary, recipient postal code : T2N 1N4, program name english : nan, program name french : nan, program purpose english : nan, program purpose french : nan, agreement title english : nan, agreement title french : nan, agreement number : nan, agreement value : 522880.0, agreement start date : 2013-04-01, agreement end date : 2017-03-31, description english : Bortezomib mediated BRCAness in Myeloma cells: novel therapeutic approach combining PARP1-2 and 26S proteasome inhibitors., description french : Bortezomib mediated BRCAness in Myeloma cells: novel therapeutic approach combining PARP1-2 and 26S proteasome inhibitors., expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year.
(2013-14 to 2016-17), additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier.
(2013-14 à 2016-17), owner organization : cihr-irsc, owner organization title : Canadian Institutes of Health Research | Instituts de recherche en santé du Canada